Status: Closed funding calls

£3 million fund to accelerate development of new cystic fibrosis therapies

LifeArc, as part of the CF AMR Syndicate, is providing £3 million in collaborative funding to drug discovery innovators to accelerate the development of new treatments for people with cystic fibrosis.


The call was for researchers in academia and small and medium enterprises (SMEs) worldwide with projects expected to last up to two years, and total funding of up to £500,000 per project.

Successful applicants will benefit from a truly collaborative approach to drug development, with access to expert advice and practical support from managing partners Medicines Discovery Catapult (MDC), LifeArc and Cystic Fibrosis Trust.

The CF Syndicate in AMR is a cross-sector initiative that brings together leading experts in CF and AMR from industry, academia and the clinic with people with CF to accelerate the translation of CF antimicrobials to the clinic and bring new and effective treatment options to people with CF. The Syndicate was established in 2019 and is jointly managed by Medicines Discovery Catapult, Cystic Fibrosis Trust and LifeArc.

Funding available

This fund is now closed to new applications.

Process and timelines

Application stepDate
Call for expression of interest (EOI) opened:30 March 2023
Call for expression of interest (EOI) closed:9 May 2023
Workshop for shortlisted applicants:June 2023
Shortlisted applicants invited to full applicationJune 2023
Full applications due:28 July 2023
Final decision:October 2023
Project start date:By the end of 2023
This funding call is no longer open to applications.
WordPress development by Andy White using PorterWP